Yazid Zalai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yazid Zalai has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cora Burgwinkel
Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science and Research Synthesis (CRS), University of Zurich
1 shared publication - Giulia Varvarà
Univ Rennes, CHU Rennes, Inserm, Institut de recherche en santé, environnement et travail (Irset)-UMR_S 1085, Rennes, France
1 shared publication - Grigorius Papapostolou
Health Data Science Center, Berlin Institute of Health at Charite, Universitaetsmedizin Berlin, Berlin, Germany
1 shared publication - Han Chang Chiam
Center for Medical Data Science Medical University of Vienna Vienna Austria
1 shared publication - Jifan Wang
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication - Ka Hin Tai
Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, F-35000 Rennes, France
1 shared publication
Latest Publications
- Open Access
Supporting Reanalysis and Reuse of Clinical Trial Data: A Case Study
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.
Open AccessSupporting Reanalysis and Reuse of Clinical Trial Data: A Case Study
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.